Vaso Corporation CEO Reflects on a Year of Growth and Innovation in End-of-Year Letter Setting the Tone for a Promising 2025
Vaso Corporation 137 Commercial Street Plainview, New York 11803 Tel: (516) 997-4600 Fax: (516) 997-2299 |
NEWS RELEASE
PLAINVIEW, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) — Vaso Corporation (“Vaso”) (OTCQX: VASO), a leader in human capital, information technology and MedTech, today released a letter to shareholders and employees summarizing the company’s achievements throughout the year and outlining key strategic developments and priorities for the upcoming year.
Highlights in the letter include operational developments, product updates, financial performance, and insights on thought-leadership initiatives. The goal is also to provide a business outlook and priorities for the year ahead.
To access the CEO Shareholder Letter, please visit: https://vasocorporation.com/category/news/
About Vaso Corporation
Headquartered in Plainview New York, Vaso Corporation is a leading human capital, information technology and MedTech business with a focus on healthcare professional sales services, network and IT services across sectors, and proprietary medical products. Vaso Corporation is a diversified organization with three core businesses operating as wholly-owned subsidiaries: VasoHealthcare, the professional sales service arm for GEHealthCare’s diagnostic imaging and ultrasound products; VasoTechnology, an information technology and managed connectivity leader serving customers in healthcare provision and other sectors; and VasoMedical, the designer and manufacturer of proprietary medical devices including Biox series devices and the developer and operator of the ARCS cloud-based SaaS platform.
For additional information, please visit www.vasocorporation.com or contact us at
info@vasocorporation.
Investor Contacts:
Michael J. Beecher
Investor Relations
Phone: 516-508-5840
Email: mbeecher@vasocorporation.com
V&S Strategic Consulting ir@vasocorporation.com
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “optimistic”, “plans”, “potential”, “looking forward”, and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions, including the possibility of a downturn in the US economy and the continued impact of the COVID-19 pandemic; the effect of the dramatic changes taking place in IT and healthcare; continuation of the GEHC agreement; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
# # #